Xact Kapitalforvaltning AB grew its position in Zoetis Inc (NYSE:ZTS) by 93.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,432 shares of the company’s stock after acquiring an additional 83,742 shares during the period. Xact Kapitalforvaltning AB’s holdings in Zoetis were worth $17,459,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Corient Capital Partners LLC lifted its stake in shares of Zoetis by 22.7% during the 1st quarter. Corient Capital Partners LLC now owns 4,172 shares of the company’s stock worth $420,000 after buying an additional 772 shares during the last quarter. AJO LP lifted its stake in shares of Zoetis by 3.2% during the 1st quarter. AJO LP now owns 1,549,593 shares of the company’s stock worth $155,998,000 after buying an additional 48,435 shares during the last quarter. Nvwm LLC lifted its stake in shares of Zoetis by 2.0% during the 1st quarter. Nvwm LLC now owns 20,630 shares of the company’s stock worth $2,077,000 after buying an additional 398 shares during the last quarter. Bluestein R H & Co. lifted its stake in shares of Zoetis by 77.8% during the 1st quarter. Bluestein R H & Co. now owns 200,667 shares of the company’s stock worth $20,201,000 after buying an additional 87,793 shares during the last quarter. Finally, NumerixS Investment Technologies Inc lifted its stake in shares of Zoetis by 319.6% during the 1st quarter. NumerixS Investment Technologies Inc now owns 40,386 shares of the company’s stock worth $4,014,000 after buying an additional 30,761 shares during the last quarter. 90.20% of the stock is owned by institutional investors.
Shares of Zoetis stock traded up $0.39 during midday trading on Tuesday, hitting $113.86. 1,667,791 shares of the company traded hands, compared to its average volume of 2,242,736. The stock has a market capitalization of $54.03 billion, a PE ratio of 36.38, a price-to-earnings-growth ratio of 2.82 and a beta of 0.87. The company has a debt-to-equity ratio of 2.84, a quick ratio of 2.79 and a current ratio of 4.05. The business has a fifty day simple moving average of $106.16. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $116.47.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is 21.09%.
In other news, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $101.89, for a total value of $203,780.00. Following the transaction, the insider now owns 30,727 shares in the company, valued at approximately $3,130,774.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,900 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the transaction, the director now owns 2,816 shares in the company, valued at approximately $311,393.28. The disclosure for this sale can be found here. Insiders have sold a total of 78,614 shares of company stock worth $8,096,895 over the last three months. Insiders own 0.29% of the company’s stock.
Several brokerages have weighed in on ZTS. BMO Capital Markets lifted their price objective on shares of Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. UBS Group began coverage on shares of Zoetis in a research note on Wednesday, March 20th. They issued a “neutral” rating for the company. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $97.00 to $110.00 in a research note on Monday, March 4th. Craig Hallum reiterated a “buy” rating and issued a $132.00 price objective (up previously from $114.00) on shares of Zoetis in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 price objective (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average price target of $108.25.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Dividend Achievers
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.